Seventure Partners racks up about $176 mln for microbiome fund

By Iris Dorbian — 2 months ago

Seventure Partners has raised 160 million euros (about $176 million) for its microbiome-focused Health for Life Capital fund. Novartis Pharma AG recently joined the fund’s investor base. Health for Life Capital’s other backers include Danone, Tereos, Lesaffre, Bel, Tornier and the Danish Technology Institute. Since launching in December 2013, the fund has made undisclosed investments in a number of companies that include Enterome, LNC, Maat pharma, Eligo bioscience, Targedys and Micropharma.

Continue

Seventure beefs up investment committee with two additions

By Iris Dorbian — 8 months ago

Seventure Partners has added Danilo Casadei Massari and Dr. Thomas Werner to its health for life capital fund investment committee. Massari was a founder and president of CM&D Pharma Ltd, which was sold to Nestle Health Science while Werner is a former managing director at Glaxo SmithKline Germany.

Continue

Humedics nabs Series C funds

By Iris Dorbian — 1 year ago

Humedics has raised more than 6.3 million euros in Series C funding. Vesalius Biocapital Partners and Seventure Partners led the round. Based in Berlin, Humedics has developed a breath analysis device that measures the liver function of patients.

Continue

Mint Solutions bags Series A funds

By Iris Dorbian — 2 years ago

Mint Solutions said Tuesday that it has secured 4.425 million euros in Series A financing. The investors included Life Sciences Partners and Seventure Partners. In conjunction with the funding, Anne Portwich of LSP and Eric de La Fortelle of Seventure Partners have been added to Mint Solutions’ board of directors. Mint Solutions is is a developer of MedEye, which helps patients get the right medication at the right time.

Continue

RuiYi and arGEN-X Announce License Agreement

By Angela Sormani — 3 years ago

arGEN-X BV has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X. arGEN-X is backed by OrbiMed Advisors, Seventure Partners, Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB.

Continue

Domain Therapeutics Completes Financing Round

By Angela Sormani — 4 years ago

Domain Therapeutics has completed a 2 million euro ($2.5 million) financing round. The biopharmaceutical company is based in Strasbourg, France. Half of the funds have been provided by a new investor, Seventure Partners and the other half has been committed by another new investor, SODIV and Domain’s existing shareholders – AIRFI, IP Growth, Auriga and […]

Continue

arGEN-X Inks $37M Series B

4 years ago

arGEN-X, a biopharmaceutical company developing human monoclonal antibodies, has raised 27.5 million euro ($37 million) in Series B financing. OrbiMed Advisors and Seventure Partners co-led the round, which included participation from existing shareholders Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB. Mike Sheffery of OrbiMed will join the company’s board.

Continue

PhosphonicS Raises £3.5 Million

By PEHub Administrator — 6 years ago

PhosphonicS, a UK-based developer of precious metal scavenger products, has raised £3.5 million in second-round funding. Seventure Partners led the round, and was joined by return backers like Regents Park Partners. PhosphonicS is a spinout from Queen Mary University of London.

Continue

BiancaMed Raises €6 Million

By PEHub Administrator — 7 years ago

BiancaMed, a Dublin, Ireland-based developer of sleep monitoring technology for conditions like sleep apnea, has raised €6 million in second-round funding. Seventure Partners led the round, and was joined by return backers ePlanet, Enterprise Ireland and ResMed. Go4Ventures served as placement agent.

Continue